Video

What to Expect When Going on a PARP Inhibitor for Ovarian Cancer

Chemotherapy and PARP inhibitors may share some side effects, but there are some major differences between the two when it comes to treating ovarian cancer.

PARP inhibitors are different than most other ovarian cancer treatments because they are oral agents administered daily.

However, according to Ursula A. Matulonis, M.D., chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, there are some unifying side effects between PARP inhibitors and traditional ovarian cancer treatments, such as chemotherapy. These include fatigue and gastrointestinal issues.

While, chemotherapy-induced side effects can be long-lasting, most associated with PARP inhibitors stop after about four to six weeks of treatment, she added.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Minimally Invasive Surgery Transforms Lung Cancer Recovery
Image of woman with text.
Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun.
Six-time cancer survivor Staci Kirk urges patients to trust their bodies and speak up to ensure their needs are understood and addressed throughout cancer care.
Certain treatments may accelerate aging in survivors, but tailored care and healthy habits can help reduce long-term risks, researchers said.
Image of man with text.
Image of woman with text.
Image of man with text.
Image of Staci.
Image of woman, with text.
Related Content